Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells

Mitsuyasu, Ronald T.; Merigan, Thomas C.; Carr, Andrew; Zack, Jerome A.; Winters, Mark A.; Workman, Cassy; Bloch, Mark; Lalezari, Jacob; Becker, Stephen; Thornton, Lorna; Akil, Bisher; Khanlou, Homayoon; Finlayson, Robert; McFarlane, Robert; Smith, Don E.; Garsia, Roger; Ma, David; Law, Matthew; Murray, John M.; von Kalle, Christof
March 2009
Nature Medicine;Mar2009, Vol. 15 Issue 3, p285
Academic Journal
Gene transfer has potential as a once-only treatment that reduces viral load, preserves the immune system and avoids lifetime highly active antiretroviral therapy. This study, which is to our knowledge the first randomized, double-blind, placebo-controlled, phase 2 cell-delivered gene transfer clinical trial, was conducted in 74 HIV-1–infected adults who received a tat-vpr–specific anti-HIV ribozyme (OZ1) or placebo delivered in autologous CD34+ hematopoietic progenitor cells. There were no OZ1-related adverse events. There was no statistically significant difference in viral load between the OZ1 and placebo group at the primary end point (average at weeks 47 and 48), but time-weighted areas under the curve from weeks 40–48 and 40–100 were significantly lower in the OZ1 group. Throughout the 100 weeks, CD4+ lymphocyte counts were higher in the OZ1 group. This study indicates that cell-delivered gene transfer is safe and biologically active in individuals with HIV and can be developed as a conventional therapeutic product.


Related Articles

  • Rapid Turnover of 2-LTR HIV-1 DNA during Early Stage of Highly Active Antiretroviral Therapy. Zhu, Weijun; Jiao, Yanmei; Lei, Rongyue; Hua, Wei; Wang, Rui; Ji, Yunxia; Liu, Zhiying; Wei, Feili; Zhang, Tong; Shi, Xuanlin; Wu, Hao; Zhang, Linqi // PLoS ONE;2011, Vol. 6 Issue 6, p1 

    Background: Despite prolonged treatment with highly active antiretroviral therapy (HAART), the infectious HIV-1 continues to replicate and resides latently in the resting memory CD4+ T lymphocytes, which blocks the eradication of HIV-1. The viral persistence of HIV-1 is mainly caused by its...

  • Evaluation of WHO immunologic criteria for treatment failure: implications for detection of virologic failure, evolution of drug resistance and choice of second-line therapy in India. Vallabhaneni, Snigdha; Chandy, Sara; Heylen, Elsa; Ekstrand, Maria L. // Journal of the International AIDS Society;2013, Vol. 16 Issue 1, p1 

    Introduction: Routine HIV viral load (VL) testing is not available in India. We compared test performance characteristics of immunologic failure (IF) against the gold standard of virologic failure (VF), examined evolution of drug resistance among those who stayed on a failing regimen because...

  • Successful antiretroviral therapy by using unusual antiretroviral combinations in heavily pre-treated patients: two case reports. Taramasso, Lucia; Dentone, Chiara; Alessandrini, Anna; Bruzzone, Bianca; Icardi, Giancarlo; Garraffo, Rodolphe; De Macina, Ilaria; Viscoli, Claudio; Di Biagio, Antonio; HIV/HCV Collaborative Liguria Group // International Journal of STD & AIDS;Oct 2015, Vol. 26 Issue 11, p831 

    In the context of HIV-infected patients with several past antiretroviral therapies and multiple failures, it is possible to be faced with viruses resistant to all drug classes. We report on two HIV-1 infected patients in which the historical genotype showed mutations against all the major drug...

  • The Effect of early treatment on the latent reservoir of HIV-1. Blankson, Joel N.; Siliciano, Janet D.; Siliciano, Robert F. // Journal of Infectious Diseases;5/1/2005, Vol. 191 Issue 9, p1394 

    The article reports that twenty-four years after the first cases of AIDS were reported, it remains unclear when therapy for HIV-1 infection should be initiated. The current U.S. Department of Health and Human Services guidelines suggest that treatment can be deferred until CD4+ T cell counts...

  • Engineering T Cells to Functionally Cure HIV-1 Infection. Leibman, Rachel S; Riley, James L // Molecular Therapy;Jul2015, Vol. 23 Issue 7, p1149 

    Despite the ability of antiretroviral therapy to minimize human immunodeficiency virus type 1 (HIV-1) replication and increase the duration and quality of patients' lives, the health consequences and financial burden associated with the lifelong treatment regimen render a permanent cure highly...

  • HIV-1 Entry Inhibitors: Classes, Applications and Factors Affecting Potency. Sterjovski, Jasminka; Churchill, Melissa J.; Wesselingh, Steve L.; Gorry, Paul R. // Current HIV Research;Oct2006, Vol. 4 Issue 4, p387 

    Antiviral agents targeting human immunodeficiency virus type-1 (HIV-1) attachment, co-receptor engagement and fusion, collectively referred to as entry inhibitors, are emerging as promising therapeutic agents in the treatment of HIV-1 infection. Viral evolution and concomitant emergence of...

  • Modelling the Impact of Antiretroviral Therapy on the Epidemic of HIV. Williams, Brian G.; Lima, Viviane; Gouws, Eleanor // Current HIV Research;Sep2011, Vol. 9 Issue 6, p367 

    Thirty years after HIV first appeared it has killed close to 30 million people but transmission continues unchecked. In 2009, an estimated 1.8 million lives were lost and 2.6 million more people were infected with HIV [1]. To cut transmission, many social, behavioural and biomedical...

  • PHARMACOLOGY AND CELL METABOLISM: The Influence of Different Types of Alcoholic Beverages on Disrupting Highly Active Antiretroviral Treatment (HAART) Outcome. Míguez-Burbano, María José; Lewis, John E.; Fishman, Joel; Asthana, Deshratn; Malow, Robert M. // Alcohol & Alcoholism;Jul/Aug2009, Vol. 44 Issue 4, p366 

    Aims: Studies have yielded conflicting results regarding alcohol's influence on HIV outcomes, particularly after highly active antiretroviral treatment (HAART). Discrepant findings may be related to confounding variables, including gender, patterns of alcohol abuse and type of alcohol beverage...

  • Viral Load in Spanish HIV patients: trends since the introduction of HAART. Eiros, J. M.ª; Sánchez-Padilla, E.; Luquero, F. J.; Nogueira, B.; Rojo, S.; Atienza-Herrero, J.; Ortiz de Lejarazu, R. // Revista Española de Quimioterapia;2009, Vol. 22 Issue 1, p34 

    The aim of this study is to describe trends in the percentage of samples with undetectable HIV viral load in Spain after the implementation of HAART. A descriptive observational study of HIV-VL measurements carried out in the microbiology department of the Hospital Clínico Universitario de...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics